]> 2026-04-12T04:11:33-07:00 Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine 0 en While specific side effects are not detailed, similar vaccines have been associated with manageable side effects like flu-like symptoms, suggesting a relatively low toxicity level. 2025-01-18T08:27:29Z 2460693.852419 Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","A variation in the use of dendritic cells first subjected tumor tissue to a heat-shock\ntreatment to elevate the expression of heat-shock proteins, which were extracted from the\nblood and incubated with dendritic cells from individual patients. In a clinical trial (163)\nconducted at UCSF and Columbia for patients with recurrent heavily pretreated tumors,\nthe vaccine produced a median survival of 42.6 weeks (about 9.8 months), which\ncompares favorably to the 6-month survival time for historical controls, and is\ncomparable to the 9-11 months when Avastin is used with patients with recurrent tumors.\n\nA subsequent news release from Agenus, Inc, a biotech company sponsoring the research,\nreported the results of phase II clinical trial in which the heat-shock dendritic vaccine was\ncombined with the standard Stupp protocol (164). Median progression-free survival was\n17.8 months and median survival was 23.8 months. This median progression-free\nsurvival of 17.8 months is perhaps the longest PFS yet seen in any\nsubstantially sized phase 2 trial for newly diagnosed glioblastoma.\n\nFollow-up data (reference 339, abstract 2011) presented at the ASCO 2015 conference\nrevealed that patients with high PD-L1 expression (the ligand for the PD-1 immune\ncheckpoint on the surface of immune cells which is the target for the therapeutic\nantibodies nivolumab and pembrolizumab) had a median survival of 18 months, while\nthose with low expression of PD-L1 had a median survival of 44.7 months. This finding\nsuggests that efficacy of the heat shock protein peptide vaccine could be greatly improved\nby co-administration of PD-1 antibodies such as nivolumab or pembrolizumab."] Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name